Astrazeneca (AZN) Other Non-Current Liabilities (2009 - 2026)
Astrazeneca (AZN) posted quarterly Other Non-Current Liabilities of $2.0 billion for Q2 2026, up 23.19% year-over-year from $1.6 billion in Q2 2025, and up 318.03% quarter-over-quarter from -$904.0 million in Q1 2026.
Astrazeneca (AZN) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Astrazeneca's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.0 billion for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 23.19% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $2.0 billion (up 23.19% YoY), while the FY2025 annual figure was $2.4 billion, up 34.41% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $2.0 billion, up from -$904.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.3 billion in Q4 2022, with the low at -$1.4 billion in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is -$922.0 million (2022), against an average of $67.2 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities slumped 105.83% in 2022, then soared 236.99% in 2025.
- Astrazeneca's Other Non-Current Liabilities stood at $4.3 billion in 2022, then slumped by 37.7% to $2.7 billion in 2023, then plunged by 33.46% to $1.8 billion in 2024, then soared by 34.41% to $2.4 billion in 2025, then declined by 17.15% to $2.0 billion in 2026.
- Business Quant data shows AZN's Other Non-Current Liabilities at $2.0 billion in Q2 2026, -$904.0 million in Q1 2026, and $2.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.97 Bn |
| Mar 31, 2026 | -904.00 Mn |
| Dec 31, 2025 | 2.38 Bn |
| Sep 30, 2025 | -1.18 Bn |
| Jun 30, 2025 | 1.60 Bn |
| Mar 31, 2025 | -1.15 Bn |
| Dec 31, 2024 | 1.77 Bn |
| Sep 30, 2024 | -1.19 Bn |
| Jun 30, 2024 | -1.17 Bn |
| Mar 31, 2024 | -1.15 Bn |
| Dec 31, 2023 | 2.66 Bn |
| Sep 30, 2023 | -1.19 Bn |
| Jun 30, 2023 | -1.36 Bn |
| Mar 31, 2023 | -914.00 Mn |
| Dec 31, 2022 | 4.27 Bn |
| Sep 30, 2022 | -930.00 Mn |
| Jun 30, 2022 | -892.00 Mn |
| Mar 31, 2022 | -1.42 Bn |
| Dec 31, 2021 | 4.93 Bn |
| Sep 30, 2021 | -972.00 Mn |